Ipsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript

2025-04-16 11:33:04 ET

Ipsen S.A. (IPSEY)

Q1 2025 Results Conference Call

April 16, 2025 08:00 AM EDT

Company Participants

David Loew - Chief Executive Officer

Aymeric Le Chatelier - Chief Financial Officer

Conference Call Participants

Shan Hama - Jefferies

John Priestner - JPMorgan

Florent Cespedes - Bernstein

Xian Deng - UBS

Simon Baker - Redburn Atlantic

Manos Mastorakis - Deutsche Bank

Alistair Campbell - RBC

Laura Hindley - Morgan Stanley

Presentation

Operator

Hello, and welcome to Ipsen’s Conference Call and Webcast for the First Quarter 2025 Results. I’ll now hand you over to David Loew, Ipsen’s CEO.

David Loew

Thank you, and hello, everyone. I am delighted to welcome you to our Q1 sales presentation this afternoon, which can also be found on ipsen.com. Please turn to Slide 2. Please take note of our forward-looking statements, which outline the routine risks and uncertainties contained within this presentation. Also, any of my commentary on growth will be based on constant exchange rates.

Please turn to Slide 3. I am going to take you through our sales performance of the first quarter, I’ll provide you with the business update of the which our CFO, Aymeric Le Chatelier, will drive me forward the question-and-answer session.

Let’s begin by looking at today’s highlights. Please turn to Slide 4. We continue to deliver a strong top-line growth in quarter one. Total sales grew by 11.6% driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay. Since the beginning of the year, we have made good progress with our pipeline including the EMA regulatory submission of the Tovorafenib for the pediatric low-grade glioma. The entry in Phase 1 of the third generation RAF inhibitor complementing our ERK inhibitor with both being in the clinic. ...

Read the full article on Seeking Alpha

For further details see: